Table 1.
Clinical and histopathological characteristics of the total cohort and of LMS patients
| Characteristics total cohort | Characteristics of LMS patients number percentage | |||
|---|---|---|---|---|
| Number | Percentage | |||
| Age at diagnosis | 51 years ± 12.2 | 51 years ± 11.4 | ||
| Histological subtype | ||||
| LMS | 44 | 77.2 | ||
| LG-ESS | 7 | 12.3 | ||
| HG-ESS | 4 | 7.0 | ||
| UUS | 2 | 3.5 | ||
| Menstrual status | ||||
| Premenopausal | 26 | 45.6 | 21 | 47.7 |
| Postmenopausal | 26 | 45.6 | 18 | 40.9 |
| Missing data | 5 | 8.8 | 5 | 11.4 |
| FIGO stage | ||||
| Stage I | 36 | 63.2 | 30 | 68.2 |
| Stage II | 7 | 12.3 | 3 | 6.8 |
| Stage III | 3 | 5.3 | 3 | 6.8 |
| Stage IV | 11 | 19.3 | 7 | 15.9 |
| Missing data | 1 | 1.8 | 1 | 2.3 |
| Tumor grading | ||||
| Grade 1 | 11 | 19.3 | 4 | 9.1 |
| Grade 2 | 13 | 22.8 | 13 | 29.5 |
| Grade 3 | 19 | 33.3 | 13 | 29.5 |
| Missing data | 14 | 24.6 | 14 | 31.8 |
| Progesterone receptor status | ||||
| PR + | 20 | 35.1 | 17 | 38.6 |
| PR− | 16 | 28.1 | 6 | 13.6 |
| Missing data | 21 | 36.8 | 21 | 47.7 |
LMS Leiomyosarcoma, LG-ESS low-grade endometrial stromal sarcoma, HG-ESS high-grade ESS, UUS undifferentiated uterine sarcoma, FIGO International Federation of Gynecology and Obstetrics, PR progesterone receptor